which glp-1 has less side effects medication for diabetes and weight loss A monthly GLP-1 dose could

Cell 168(5):758774 Frias JP, Bonora E, Nevarez Ruiz L et al (2021) Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11)

FDA source Lilly status Lilly states retatrutide is investigational and not available for public use

Include a letter of medical necessity from your provider, documentation of all qualifying comorbidities, evidence of failed prior weight loss attempts, and any supporting metabolic data

All post-hoc analyses were also performed on the Part 2 blinded extension phase of the trial, to compare the early-start group (prasinezumab for 104 weeks) and delayed-start group (placebo for 52 weeks, and then prasinezumab for 52 weeks)

A 2025 study of high dose semaglutide injection (7.2 mg) showed that adults with obesity lost around 21% of their body weight after 72 weeks

Second, unconventional sources deserve attention